IL6 and congenital rubella syndrome: Tocilizumab can effectively block the IL-6 signal transduction pathway and could conceptually become an effective drug for patients with severe COVID-19 since significant morbidity and mortality in the late phase of disease is attributed to severe cytokine release storm (CRS) [41, 42]).